

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 September 2011 (09.09.2011)

PCT

(10) International Publication Number
WO 2011/109526 A1

(51) International Patent Classification:
A01N 43/42 (2006.01) *A61K 31/47* (2006.01)

(21) International Application Number:
PCT/US2011/026879

(22) International Filing Date:
2 March 2011 (02.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/339,363 3 March 2010 (03.03.2010) US

(71) Applicant (for all designated States except BB, US):
TEVA PHARMACEUTICAL INDUSTRIES LTD.
[IL/IL]; 5 Basel Street, P.O. Box 3190, Petach-Tikva
49131 (IL).

(71) Applicant (for BB only): **TEVA PHARMACEUTI-
CALS USA, INC.** [US/US]; 1090 Horsham Road, North
Wales, PA 19454 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAVIV, Asi**
[IL/IL]; Kvut Shiller(gan Shlomo), 76802 (IL). **TARCIC,**
Nora [IL/IL]; Migdal David 29/1, Modiin (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30
Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD

(57) Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquimimod or pharmaceutically acceptable salt thereof effective to treat the subject This invention also provides laquimimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis This invention further provides a pharmaceutical composition comprising an amount of laquimimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis



WO 2011/109526 A1